New bladder cancer strategy aims to shrink tumors before surgery
NCT ID NCT05241340
Summary
This study is testing a new two-part treatment for muscle-invasive bladder cancer in patients who cannot receive standard chemotherapy. Before having their bladder surgically removed, participants receive a drug called sasanlimab (an immunotherapy) and a short, precise course of radiation. The main goal is to see if this combination can completely eliminate the cancer in the removed bladder and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77006, United States
Conditions
Explore the condition pages connected to this study.